Vivani Medical (VANI) said Thursday that it has completed enrolling participants in its initial clinical trial testing NPM-115, a subdermal GLP-1 implant for overweight adults with type 2 diabetes.
The company said the first patient received the implant as part of the study, which is designed to evaluate drug absorption and safety over a six-month period.
Vivani said the enrollment concluded about four weeks after the first subject was dosed, with preliminary results expected by mid-2025.
The company's shares were up more than 2% in recent Thursday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。